IMRN News and Press, Immuron Limited From 10/08/21

ChemoCentryx CCXI +71% on FDA approval of Tavneos for treatment of vasculitis (updated) Camber Energy (NYSE:CEI) +33%. eFFECTOR Therapeutics EFTR +22% after-hours on encouraging zotatifin data in breast cancer InflaRx N.V. (NASDAQ:IFRX) +18%. Immuron (NASDAQ:IMRN) +16%. Fo...

Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical models and a phase I/IIa clinical trial: A method for the prevention a...

MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignat...

MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today would like to provide...

Key Points Monash University Research Update on SARS-CoV-2 program Biomedicine Discovery Institute initiates program to isolate and identify the inhibitory molecule/s in IMM-124E Appointment of Chief Medical Officer with preliminary focus on...

MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to announce that Ch...

Prevail Therapeutics (PRVL) +84% on being acquired by Lilly for ~$1.04B.OncoCyte Corporation (OCX) +63% after company enters agreement with Burning Rock Biotech.Anavex Life Sciences (AVXL) +40% as it's blarcamesine successful in mid-stage rett syndrome study.Mid-Con Energy Part...

Immuron (IMRN) rises 12% premarket after providing an update on progress of the anti-viral activity of IMM-124E. A new research services agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s i...

Key Points Immuron’s Hyper-immune Bovine Colostrum, used to manufacture Travelan ® and Protectyn ® , demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies. A New Research Services Agreement has been...

MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under the Austra...